Lumida
/SEPN
⌘K
Septerna Inc

Septerna Inc

SEPN
$33.40USD+5.83%+1.84 today

MARKET CAP

1.5B

P/E (TTM)

FWD P/E

DAY RANGE

$31 – $34

52W RANGE

$11
$38

AI Summary

Stalk
TrimMedium

SEPN is in a high-confidence Stage 3 distribution phase, with its higher-high/higher-low structure broken and EMAs turning down. Medium-term bias remains bearish under distribution dynamics, while short-term timing is neutral as price tests lower support. Look to sell into rallies around the 9- and 21-period EMAs for best execution.

  • Q1 2026 loss of $0.19/sh bested estimates by 55.3%, stock +8.1%
  • Cash runway of $522M via Novo Nordisk collaboration funds operations to 2029
  • Ongoing negative profitability and earnings yield indicate poor return generation
Full analysis →
Insider Trades16 trades
DateSideTickerInsiderRoleSharesPriceMkt Cap52W High52W LowValue% ChgRuleAI View
Jul 15, 2026SellSEPNElizabeth BhattPresident and COO8,000$20.40$1.5B-12.20%+214.62%$163.2K+0.00%10b5-1Trim
Jul 1, 2026SellSEPNDaniel D. LongSVP, Drug Discovery6,666$18.56$1.5B-12.20%+214.62%$123.7K+0.00%10b5-1Trim
Jun 29, 2026SellSEPNSamira ShaikhlyChief People Officer4,356$20.99$1.5B-12.20%+214.62%$91.5K+0.00%10b5-1Trim
Jun 22, 2026SellSEPNDaniel D. LongSVP, Drug Discovery30,000$20.47$1.5B-12.20%+214.62%$614.0K+0.00%10b5-1Trim
Jun 12, 2026SellSEPNSamira ShaikhlyChief People Officer12,500$23.39$1.5B-12.20%+214.62%$292.3K+0.00%10b5-1Trim
Jun 1, 2026SellSEPNSamira ShaikhlyChief People Officer11,870$15.40$1.5B-12.20%+214.62%$182.8K+0.00%10b5-1Trim
May 26, 2026SellSEPNSamira ShaikhlyChief People Officer23,596$18.44$1.5B-12.20%+214.62%$435.0K+0.00%10b5-1Trim
Apr 15, 2026SellSEPNElizabeth BhattPresident and COO8,000$15.57$1.5B-12.20%+214.62%$124.6K+0.00%10b5-1Trim
Mar 2, 2026SellSEPNSamira ShaikhlyChief People Officer140,906$14.97$1.5B-12.20%+214.62%$2.1M+0.00%10b5-1Trim
Feb 18, 2026SellSEPNElizabeth BhattPresident and COO8,000$17.89$1.5B-12.20%+214.62%$143.1K+0.00%10b5-1Trim
Nov 10, 2025SellSEPNDaniel D. LongSVP, Drug Discovery3,501$18.06$1.5B-12.20%+214.62%$63.2K-3.63%Trim
Aug 18, 2025BuySEPNUwe KleinSVP, Biological Sciences23,008$4.10$1.5B-12.20%+214.62%$94.4K+29.38%Trim
Apr 2, 2025BuySEPNJeffrey FinerCEO and President55,000$2.76$1.5B-12.20%+214.62%$151.8K+2.30%Trim
Feb 25, 2025BuySEPNGil M LabrucherieChief Financial Officer10,000$5.69$1.5B-12.20%+214.62%$56.9K+15.09%Trim
Feb 25, 2025BuySEPNJeffrey FinerCEO and President17,000$5.70$1.5B-12.20%+214.62%$97.0K+0.74%Trim
Feb 19, 2025BuySEPNGil M LabrucherieChief Financial Officer30,000$5.74$1.5B-12.20%+214.62%$172.3K+84.51%Trim